<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="first legal syringe services program (SSP) in Florida implemented routine" exact="screening" post="in 2018 leading to the identification of ten anonymous"/>
 <result pre="syringe services programs (SSPs) [8, 9]. The use of medication-assisted" exact="treatment" post="for substance use and dependence, rapid access to antiretroviral"/>
 <result pre="access to antiretroviral therapies (ART) for those living with a" exact="diagnosis" post="of HIV, pre-exposure prophylaxis (PrEP), and other harm reduction"/>
 <result pre="reduction packs, HIV/HCV testing, referrals for healthcare, housing and drug" exact="treatment" post="(including medication-assisted treatment), and linkage to HIV/HCV care and"/>
 <result pre="syringes, distributed 1859 boxes of nasal naloxone, and administered 1576" exact="screening" post="tests for HIV and HCV. On February 19, 2018,"/>
 <result pre="2018, the IDEA SSP implemented anonymous, opt-out, HIV/HCV rapid antibody" exact="screening" post="of all participants at initial enrollment into the SSP,"/>
 <result pre="all participants at initial enrollment into the SSP, including ï»¿subsequent" exact="testing" post="for those testing non-reactive every 3 months thereafter. On"/>
 <result pre="initial enrollment into the SSP, including ï»¿subsequent testing for those" exact="testing" post="non-reactive every 3 months thereafter. On March 9, 2018,"/>
 <result pre="response, the SSP partnered with DOH to provide on-site confidential" exact="testing" post="and rapid linkage to HIV care and treatment. DOH"/>
 <result pre="a Disease Intervention Specialist (DIS) within the SSP to facilitate" exact="contact tracing." post="DOH analyzed HIV-1 nucleotide sequence data to determine if"/>
 <result pre="HIV diagnoses within a suspected HIV transmission network through confidential" exact="testing" post="and contact tracing, and (3) assess care and treatment"/>
 <result pre="within a suspected HIV transmission network through confidential testing and" exact="contact tracing," post="and (3) assess care and treatment outcomes for identified"/>
 <result pre="confidential testing and contact tracing, and (3) assess care and" exact="treatment" post="outcomes for identified individuals with HIV seroconversion. Methods Ethical"/>
 <result pre="the IDEA SSP known to be living with a previous" exact="diagnosis" post="of HIV as of December 20, 2018 who had"/>
 <result pre="who had been reported to DOH. Epidemiologic Investigation Anonymous HIV" exact="testing" post="results at the IDEA SSP were recorded under an"/>
 <result pre="suspected seroconversion identified by the SSP were verified following confidential" exact="testing" post="to meet the CSTE case definition as a new"/>
 <result pre="to meet the CSTE case definition as a new HIV" exact="diagnosis" post="[20]. Individuals with a confirmed seroconversion were assigned to"/>
 <result pre="were assigned to a DIS embedded at the SSP for" exact="contact tracing" post="and partner elicitation. Blood specimens for individuals with confirmed"/>
 <result pre="assigned to a DIS embedded at the SSP for contact" exact="tracing" post="and partner elicitation. Blood specimens for individuals with confirmed"/>
 <result pre="partners whose HIV status was negative or unknown were offered" exact="screening" post="tests. For persons with a previous diagnosis of HIV,"/>
 <result pre="unknown were offered screening tests. For persons with a previous" exact="diagnosis" post="of HIV, blood samples for those missing molecular sequences"/>
 <result pre="routine control measures such as rapid access to ART and" exact="screening" post="of persons for HIV, syphilis, gonorrhea, chlamydia, and hepatitis"/>
 <result pre="B and C. Laboratory Testing Individuals were screened for HIV" exact="infection" post="using a point-of-care rapid HIV test (OraQuick ADVANCEÂ® Rapid"/>
 <result pre="OraSure Technologies). Individuals with reactive rapid tests received confidential antibody" exact="screening" post="(HIV-1/2 enzyme immunoassay) and confirmatory HIV tests (HIV-1/2 type-differentiating"/>
 <result pre="with rapid access to ART and HIV care following initial" exact="diagnosis" post="or when returning to care. Bictegravir-tenofovir alafenamide-emtricitabine (BIC/FTC/TAF) was"/>
 <result pre="to care, time to viral suppression, and coinfection or prior" exact="infection" post="with syphilis and HCV were obtained for all linked"/>
 <result pre="first reported viral load of less than 200 copies/mL. HIV" exact="diagnosis" post="date was defined as the earliest specimen collection date"/>
 <result pre="as well as other SSP participants with a previous HIV" exact="diagnosis" post="were visualized using the Harel-Koren Fast Multiscale algorithm in"/>
 <result pre="[21]. Molecular linkages, using the first reported nucleotide sequences after" exact="diagnosis" post="within the reverse transcriptase and protease section of the"/>
 <result pre="seven individuals out of ten suspected patients with an HIV" exact="diagnosis" post="met the case definition of an acute HIV seroconversion."/>
 <result pre="been previously diagnosed before implementation of the IDEA SSPâ€™s universal" exact="testing" post="protocol. Another 32 individuals participating in the SSP who"/>
 <result pre="in the SSP who were previously living with an HIV" exact="diagnosis" post="were also reviewed for molecular linkages, seven of whom"/>
 <result pre="did not have a reported genotype at the time of" exact="diagnosis" post="and were virally suppressed at the time of the"/>
 <result pre="epidemiologic and molecular linkages, Miami, FL, 2018 ID Year of" exact="diagnosis" post="Year of genotype Protease Reverse transcriptase Integrase 1 2018"/>
 <result pre="epidemics [18, 23]. In Miami-Dade County, the implementation of routine" exact="screening" post="at the SSP, early identification of individuals with recent"/>
 <result pre="transmission dynamics also highlighted the important role both traditional partner" exact="contact tracing" post="and molecular data play to supplement information and build"/>
 <result pre="dynamics also highlighted the important role both traditional partner contact" exact="tracing" post="and molecular data play to supplement information and build"/>
 <result pre="epidemiological networks. Previous studies are in agreement that complementing traditional" exact="contact tracing" post="with molecular HIV sequence data can confirm or refine"/>
 <result pre="networks. Previous studies are in agreement that complementing traditional contact" exact="tracing" post="with molecular HIV sequence data can confirm or refine"/>
 <result pre="to the organized response being delivered through the SSP. Early" exact="diagnosis" post="and immediate ART initiation was prioritized to rapidly decrease"/>
 <result pre="healthcare services. This intensive linkage and active follow-up also included" exact="counseling" post="by licensed mental health counselors at the SSP who"/>
 <result pre="recently reported that intensive and flexible patient navigation with psychosocial" exact="counseling" post="was central to increased initiation of ART and viral"/>
 <result pre="the local health department for publicly funded services for additional" exact="screening" post="and testing and adaptation of the â€œTest and Treatâ€�"/>
 <result pre="health department for publicly funded services for additional screening and" exact="testing" post="and adaptation of the â€œTest and Treatâ€� program for"/>
 <result pre="for the Study of Liver Diseases (AASLD) Guidelines for HCV" exact="treatment" post="for those co-infected with HIV. There are no current"/>
 <result pre="can be compliant with treatment. However, for this study the" exact="treatment" post="and medical records pertaining to the treatment of HCV"/>
 <result pre="this study the treatment and medical records pertaining to the" exact="treatment" post="of HCV were determined outside of the scope of"/>
 <result pre="at an SSP. The SSP played a central role in" exact="testing" post="and surveillance due to the trusted relationship with the"/>
 <result pre="linkage, and navigation in this population. Implementation of universal HIV/HCV" exact="testing" post="at the SSP provided a high yield venue to"/>
 <result pre="this SSPâ€™s role in the collaborative effort led to early" exact="detection" post="and suppression of a typically medically underserved and marginalized"/>
 <result pre="Providing concentrated wrap-around services at an SSP including implementing routine" exact="screening" post="and offering intensive linkage and patient navigation could be"/>
 <result pre="Lisa R. Metsch. The Gilead FOCUS program funded the HIV/HCV" exact="screening" post="and linkage to care. AIDS Healthcare Foundation, CAN Community"/>
 <result pre="Center at the University of Miami. References References 1.Des JarlaisDCKerrTCarrieriPFeelemyerJArastehKHIV" exact="infection" post="among persons who inject drugs: ending old epidemics and"/>
 <result pre="cultural anthropologists in the South BronxDialect Anthropol201640439541010.1007/s10624-016-9443-427917016 3.Karch D. HIV" exact="infection" post="care and viral suppression among people who inject drugs,"/>
 <result pre="drugs, 28 US Jurisdictions, 2012â€&quot;2013. 2019. 4.KimNWeltySRezaTSearsDMcFarlandWRaymondHFUndiagnosed and untreated HIV" exact="infection" post="among persons who inject drugs: results of three national"/>
 <result pre="factors, HIV-related risk, and community contextJ Commun Health20174219010010.1007/s10900-016-0234-2 6.DegenhardtLPeacockAColledgeSLeungJGrebelyJVickermanPet al.Global" exact="prevalence" post="of injecting drug use and sociodemographic characteristics and prevalence"/>
 <result pre="al.Global prevalence of injecting drug use and sociodemographic characteristics and" exact="prevalence" post="of HIV, HBV, and HCV in people who inject"/>
 <result pre="of effectivenessInt J Drug Policy2014251345210.1016/j.drugpo.2013.07.00123973009 10.ChoopanyaKMartinMSuntharasamaiPSangkumUMockPALeethochawalitMet al.Antiretroviral prophylaxis for HIV" exact="infection" post="in injecting drug users in Bangkok, Thailand (the Bangkok"/>
 <result pre="of HIV-1 transmission in New York CityPLoS Pathog2017131e100600010.1371/journal.ppat.100600028068413 18.PetersPJPontonesPHooverKWPatelMRGalangRRShieldsJet al.HIV" exact="infection" post="linked to injection use of oxymorphone in Indiana, 2014â€&quot;2015N"/>
 <result pre="transmission network analysis of a large opiate-driven outbreak of HIV" exact="infection" post="in the United StatesJ Infect Dis201721691053106210.1093/infdis/jix30729029156 25.DeckerMRWirtzALBaralSDPeryshkinaAMogilnyiVWeberRAet al.Injection drug"/>
 <result pre="Transm Infect.201288427828310.1136/sextrans-2011-05017122287530 26.BaconOLumPHahnJEvansJDavidsonPMossAet al.Commercial sex work and risk of HIV" exact="infection" post="among young drug-injecting men who have sex with men"/>
 <result pre="Health200710320421310.1111/j.1524-4733.2007.00170.x17532813 28.BernardinFKongDPeddadaLBaxter-LoweLADelwartEHuman immunodeficiency virus mutations during the 1st month of" exact="infection" post="are preferentially found in known cytotoxic T-lymphocyte epitopesJ Virol20057917115231152810.1128/JVI.79.17.11523-11528.200516103205"/>
 <result pre="in known cytotoxic T-lymphocyte epitopesJ Virol20057917115231152810.1128/JVI.79.17.11523-11528.200516103205 29.CohenMSChenYQMcCauleyMGambleTHosseinipourMCKumarasamyNet al.Prevention of HIV-1" exact="infection" post="with early antiretroviral therapyN Engl J Med2011365649350510.1056/NEJMoa110524321767103 30.DieffenbachCWFauciASUniversal voluntary"/>
 <result pre="infection with early antiretroviral therapyN Engl J Med2011365649350510.1056/NEJMoa110524321767103 30.DieffenbachCWFauciASUniversal voluntary" exact="testing" post="and treatment for prevention of HIV transmissionJAMA2009301222380238210.1001/jama.2009.82819509386 31.GranichRMGilksCFDyeCDe CockKMWilliamsBGUniversal"/>
 <result pre="early antiretroviral therapyN Engl J Med2011365649350510.1056/NEJMoa110524321767103 30.DieffenbachCWFauciASUniversal voluntary testing and" exact="treatment" post="for prevention of HIV transmissionJAMA2009301222380238210.1001/jama.2009.82819509386 31.GranichRMGilksCFDyeCDe CockKMWilliamsBGUniversal voluntary HIV"/>
 <result pre="treatment for prevention of HIV transmissionJAMA2009301222380238210.1001/jama.2009.82819509386 31.GranichRMGilksCFDyeCDe CockKMWilliamsBGUniversal voluntary HIV" exact="testing" post="with immediate antiretroviral therapy as a strategy for elimination"/>
 <result pre="observed initiation of antiretroviral therapy on HIV viral load and" exact="treatment" post="outcomes in a US public health settingJ Acquir Immune"/>
 <result pre="engage people who inject drugs in HIV care and medication-assisted" exact="treatment" post="(HPTN 074): a randomised, controlled phase 3 feasibility and"/>
</results>
